Literature DB >> 18040824

Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues.

Paul J Peters1, Maria J Dueñas-Decamp, W Matthew Sullivan, Paul R Clapham.   

Abstract

Human immunodeficiency virus (HIV)-positive individuals frequently suffer from progressive encephelopathy, which is characterized by sensory neuropathy, sensory myelopathy, and dementia. Our group and others have reported the presence of highly macrophage-tropic R5 variants of HIV-1 in brain tissue of patients with neurological complications. These variants are able to exploit low amounts of CD4 and/or CCR5 for infection and potentially confer an expanded tropism for any cell types that express low CD4 and/or CCR5. In contrast to the brain-derived envelopes, we found that envelopes from lymph node tissue, blood, or semen were predominantly non-macrophage-tropic and required high amounts of CD4 for infection. Nevertheless, where tested, the non-macrophage-tropic envelopes conferred efficient replication in primary CD4(+) T-cell cultures. Determinants of R5 macrophage tropism appear to involve changes in the CD4 binding site, although further unknown determinants are also involved. The variation of R5 envelopes also affects their sensitivity to inhibition by ligands and entry inhibitors that target CD4 and CCR5. In summary, HIV-1 R5 viruses vary extensively in macrophage tropism. In the brain, highly macrophage-tropic variants may represent neurotropic or neurovirulent viruses. In addition, variation in R5 macrophage tropism may also have implications (1) for transmission, depending on what role macrophages or cells that express low CD4 and/or CCR5 play in the establishment of infection in a new host, and (2) for pathogenesis and depletion of CD4(+) T cells (i.e., do highly macrophage-tropic variants confer a broader tropism among CD4(+) T-cell populations late in disease and contribute to their depletion?).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18040824     DOI: 10.1007/s11481-006-9042-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  83 in total

1.  Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient?

Authors:  J L Lathey; D Brambilla; M M Goodenow; M Nokta; S Rasheed; E B Siwak; J W Bremer; D D Huang; Y Yi; P S Reichelderfer; R G Collman
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

Review 2.  Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS.

Authors:  Kenneth C Williams; William F Hickey
Journal:  Annu Rev Neurosci       Date:  2002-03-27       Impact factor: 12.449

3.  Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry.

Authors:  K Takahashi; S L Wesselingh; D E Griffin; J C McArthur; R T Johnson; J D Glass
Journal:  Ann Neurol       Date:  1996-06       Impact factor: 10.422

Review 4.  Mechanisms of the blood-brain barrier disruption in HIV-1 infection.

Authors:  Michal Toborek; Yong Woo Lee; Govinder Flora; Hong Pu; Ibolya E András; Edward Wylegala; Bernhard Hennig; Avindra Nath
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

5.  Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis.

Authors:  Paul J Peters; W Matthew Sullivan; Maria J Duenas-Decamp; Jayanta Bhattacharya; Chiambah Ankghuambom; Richard Brown; Katherine Luzuriaga; Jeanne Bell; Peter Simmonds; Jonathan Ball; Paul R Clapham
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 6.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

7.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

Review 8.  Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex.

Authors:  H S Nottet; H E Gendelman
Journal:  Immunol Today       Date:  1995-09

9.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

10.  Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS.

Authors:  K C Williams; S Corey; S V Westmoreland; D Pauley; H Knight; C deBakker; X Alvarez; A A Lackner
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  21 in total

1.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 2.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

Review 3.  Bioinformatic analysis of HIV-1 entry and pathogenesis.

Authors:  Benjamas Aiamkitsumrit; Will Dampier; Gregory Antell; Nina Rivera; Julio Martin-Garcia; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

Review 4.  Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.

Authors:  Andrew W Woodham; Joseph G Skeate; Adriana M Sanna; Julia R Taylor; Diane M Da Silva; Paula M Cannon; W Martin Kast
Journal:  AIDS Patient Care STDS       Date:  2016-07       Impact factor: 5.078

5.  Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment.

Authors:  Luna Li; Benjamas Aiamkitsumrit; Vanessa Pirrone; Michael R Nonnemacher; Adam Wojno; Shendra Passic; Katherine Flaig; Evelyn Kilareski; Brandon Blakey; Jade Ku; Nirzari Parikh; Rushabh Shah; Julio Martin-Garcia; Brian Moldover; Laila Servance; David Downie; Sharon Lewis; Jeffrey M Jacobson; Dennis Kolson; Brian Wigdahl
Journal:  J Neurovirol       Date:  2011-01-12       Impact factor: 2.643

Review 6.  HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies.

Authors:  Paul R Gorry; Nicholas Francella; Sharon R Lewin; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2013-10-24       Impact factor: 4.962

7.  Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Authors:  Li-Hua Ping; Sarah B Joseph; Jeffrey A Anderson; Melissa-Rose Abrahams; Jesus F Salazar-Gonzalez; Laura P Kincer; Florette K Treurnicht; Leslie Arney; Suany Ojeda; Ming Zhang; Jessica Keys; E Lake Potter; Haitao Chu; Penny Moore; Maria G Salazar; Shilpa Iyer; Cassandra Jabara; Jennifer Kirchherr; Clement Mapanje; Nobubelo Ngandu; Cathal Seoighe; Irving Hoffman; Feng Gao; Yuyang Tang; Celia Labranche; Benhur Lee; Andrew Saville; Marion Vermeulen; Susan Fiscus; Lynn Morris; Salim Abdool Karim; Barton F Haynes; George M Shaw; Bette T Korber; Beatrice H Hahn; Myron S Cohen; David Montefiori; Carolyn Williamson; Ronald Swanstrom
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

8.  Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Authors:  Hamid Salimi; Michael Roche; Nicholas Webb; Lachlan R Gray; Kelechi Chikere; Jasminka Sterjovski; Anne Ellett; Steve L Wesselingh; Paul A Ramsland; Benhur Lee; Melissa J Churchill; Paul R Gorry
Journal:  J Leukoc Biol       Date:  2012-10-17       Impact factor: 4.962

Review 9.  Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.

Authors:  Kelechi Chikere; Tom Chou; Paul R Gorry; Benhur Lee
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

10.  R5 Macrophage-Tropic HIV-1 in the Male Genital Tract.

Authors:  Maria M Bednar; Blake M Hauser; Li-Hua Ping; Elena Dukhovlinova; Shuntai Zhou; Kathryn T Arrildt; Irving F Hoffman; Joseph J Eron; Myron S Cohen; Ronald Swanstrom
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.